Drugs / PL-ASA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04811625 | Apr → Sep 2021 | — | PLx Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL-ASA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04811625 ↗ |
| Known as | phospholipid-aspirin | “Phospholipid-aspirin liquid filled capsules (PL-ASA) are a novel FDA-approved immediate-release formulation designed to reduce gastrointestinal (GI) injury by limiting direct...” PMID 36036856 ↗ Aug 2022 |